San Antonio Breast Cancer Symposium

San Antonio Breast Cancer Symposium

December 21, 2016
3 min watch
Save

VIDEO: Combination active in subset of women with triple-negative breast cancer

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SAN ANTONIO — The combination of mifepristone and eribulin appeared active in women with recurrent, glucocorticoid receptor–positive triple-negative breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

Sharon Wilks, MD, FACP — medical oncologist with Texas Oncology, a practice in The US Oncology Network — and colleagues also found the combination to be well tolerated.

“It’s really important to know when you’re struggling with a patient who has had recurrent disease that ... you can find targets that may actually be very effective,” Wilks said. – by Kristie L. Kahl

Disclosure: Wilks reports no relevant financial disclosures.